Cardiogenic Shock disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: CRD137 MIFTS: 54	Cardiogenic Shock Categories: Blood diseases, Cardiovascular diseases, Rare diseases	Data Licensing For inquiries, contact: [email protected]
Genes Tissues Related diseases Publications Symptoms & Phenotypes Drugs Expand all tables

Sources

Aliases & Classifications for Cardiogenic Shock

MalaCards integrated aliases for Cardiogenic Shock:

Name: Cardiogenic Shock ⁵⁸ ⁶³ ⁷⁵ ³¹

Shock, Cardiogenic ⁷¹

Shock Cardiogenic ⁵³

Characteristics:

Prevelance:

1-5/10000 (Europe) ⁵⁸

Age Of Onset:

Adolescent,Adult,Childhood,Elderly ⁵⁸

Classifications:

MalaCards categories:
Global: Rare diseases
Anatomical: Cardiovascular diseases Blood diseases

See all MalaCards categories (disease lists)

ICD10: ³¹ ³²

Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified

General symptoms and signs

Shock, not elsewhere classified

Cardiogenic shock

Sources

Summaries for Cardiogenic Shock

PubMed Health : ⁶³ Cardiogenic shock: Cardiogenic (kar-dee-oh-JE-nik) shock is a condition in which a suddenly weakened heart isn't able to pump enough blood to meet the body's needs. The condition is a medical emergency and is fatal if not treated right away. The most common cause of cardiogenic shock is damage to the heart muscle from a severe heart attack. However, not everyone who has a heart attack has cardiogenic shock. In fact, on average, only about 7 percent of people who have heart attacks develop the condition. If cardiogenic shock does occur, it's very dangerous. When people die from heart attacks in hospitals, cardiogenic shock is the most common cause of death.

MalaCards based summary: Cardiogenic Shock, also known as shock, cardiogenic, is related to mitral valve insufficiency and myocardial infarction, and has symptoms including syncope and shock without mention of trauma. An important gene associated with Cardiogenic Shock is NPPB (Natriuretic Peptide B), and among its related pathways/superpathways are MicroRNAs in cardiomyocyte hypertrophy and NO/cGMP/PKG mediated neuroprotection. The drugs Benzocaine and Tannic acid have been mentioned in the context of this disorder. Affiliated tissues include heart, skeletal muscle and kidney, and related phenotypes are hypotension and low-output congestive heart failure

Orphanet: ⁵⁸ A rare, cardiac condition characterized by severely decreased cardiac output, hypoperfusion and end-organ dysfunction, in the presence of adequate intravascular volume. The clinical presentation is variable and may range from subtle hemodynamic alterations to overt cardiovascular collapse. Commonly reported features include dyspnea, crackles, elevated jugular venous pressure, altered mental state, abnormal pulse pressure, oliguria, cold extremities, and increased serum lactate levels.

Wikipedia: ⁷⁵ Cardiogenic shock (CS) is a medical emergency resulting from inadequate blood flow due to the... more...

Sources

Related Diseases for Cardiogenic Shock

Diseases related to Cardiogenic Shock via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 545)

#	Related Disease	Score	Top Affiliating Genes
1	mitral valve insufficiency	31.4	NPPB NPPA
2	myocardial infarction	31.3	PLAT PIK3C2A NPPB NPPA
3	heart septal defect	31.1	NPPB NPPA
4	acute myocardial infarction	30.9	PLAT PIK3C2A NPPB NPPA
5	myocarditis	30.9	PIK3C2A NPPB NPPA
6	aortic valve disease 2	30.8	NPPB NPPA
7	acute kidney failure	30.7	PIK3C2A NPPA
8	pulmonary edema	30.7	PIK3C2A NPPB NPPA
9	atrioventricular block	30.6	PIK3C2A NPPB
10	pulmonary embolism	30.6	PLAT NPPB
11	coronary artery vasospasm	30.5	PIK3C2A NPPB
12	ventricular septal defect	30.5	NPPB NPPA
13	tricuspid valve insufficiency	30.5	PLAT NPPB
14	heart valve disease	30.5	NPPB NPPA
15	coronary stenosis	30.4	PIK3C2A NPPB
16	endocarditis	30.3	PLAT PIK3C2A
17	cardiac tamponade	30.3	PLAT PIK3C2A NPPB
18	angina pectoris	30.3	PLAT PIK3C2A NPPB
19	transient cerebral ischemia	30.3	PLAT NPPB
20	myxedema	30.2	PIK3C2A NPPA
21	mitral valve stenosis	30.2	PLAT NPPB NPPA
22	inferior myocardial infarction	30.1	PLAT PIK3C2A NPPB
23	pericardial effusion	30.1	PIK3C2A NPPB NPPA
24	disseminated intravascular coagulation	30.0	PLAT PIK3C2A
25	atrial fibrillation	30.0	PLAT NPPB NPPA
26	heart disease	30.0	PLAT PIK3C2A NPPB NPPA
27	lipoprotein quantitative trait locus	30.0	PLAT PIK3C2A NPPB NPPA
28	atrial heart septal defect	29.9	PLAT NPPB NPPA
29	acute kidney tubular necrosis	29.9	PIK3C2A NPPA
30	hypoplastic left heart syndrome	29.9	NPPB NPPA
31	toxic myocarditis	29.9	PIK3C2A NPPB
32	acute anterolateral myocardial infarction	29.8	PIK3C2A NPPB
33	malignant hypertension	29.8	NPPB NPPA
34	renovascular hypertension	29.8	NPPB NPPA
35	stroke, ischemic	29.8	PLAT NPPB NPPA
36	mitral valve disease	29.8	NPPB NPPA
37	anterolateral myocardial infarction	29.8	PLAT NPPB NPPA
38	ischemia	29.6	PLAT PIK3C2A NPPB
39	posterior myocardial infarction	29.5	PLAT PIK3C2A
40	cardiovascular system disease	29.5	PLAT NPPB NPPA
41	patent foramen ovale	29.1	PLAT PIK3C2A NPPB NPPA
42	diabetes mellitus	29.1	PLAT PIK3C2A NPPB NPPA
43	coronary artery dissection, spontaneous	11.2
44	scorpion envenomation	11.2
45	ogden syndrome	11.2
46	hantavirus pulmonary syndrome	11.2
47	pleuro-pericardial cyst	11.2
48	cardiac arrest	11.1
49	broken heart syndrome	10.9
50	pheochromocytoma	10.8

Comorbidity relations with Cardiogenic Shock via Phenotypic Disease Network (PDN): (show all 17)

Active Peptic Ulcer Disease	Acute Cystitis
Acute Kidney Failure	Aortic Valve Disease 1
Cardiac Arrest	Chronic Kidney Disease
Deficiency Anemia	Familial Atrial Fibrillation
Heart Disease	Intermediate Coronary Syndrome
Kidney Disease	Mitral Valve Disease
Peripheral Vascular Disease	Respiratory Failure
Third-Degree Atrioventricular Block	Tricuspid Valve Disease
Ventricular Fibrillation, Paroxysmal Familial, 1

Graphical network of the top 20 diseases related to Cardiogenic Shock:

Sources

Symptoms & Phenotypes for Cardiogenic Shock

Human phenotypes related to Cardiogenic Shock:

⁵⁸ ³⁰ (show all 27)

#	Description	HPO Frequency	Orphanet Frequency	HPO Source Accession
1	hypotension ⁵⁸ ³⁰	Hallmark (90%)	Very frequent (99-80%)	HP:0002615
2	low-output congestive heart failure ⁵⁸ ³⁰	Hallmark (90%)	Very frequent (99-80%)	HP:0009805
3	abnormal left ventricular function ³⁰	Hallmark (90%)		HP:0005162
4	myocardial infarction ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0001658
5	dyspnea ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0002094
6	hypoxemia ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0012418
7	oliguria ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0100520
8	cardiac arrest ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0001695
9	crackles ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0030830
10	impaired myocardial contractility ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0006670
11	elevated jugular venous pressure ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0030848
12	low pulse pressure ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0030851
13	increased pulmonary capillary wedge pressure ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0030876
14	mitral regurgitation ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0001653
15	vertigo ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0002321
16	increased serum lactate ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0002151
17	metabolic acidosis ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0001942
18	confusion ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0001289
19	st segment elevation ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0012251
20	elevated circulating creatinine concentration ³⁰	Occasional (7.5%)		HP:0003259
21	coma ⁵⁸ ³⁰	Very rare (1%)	Very rare (<4-1%)	HP:0001259
22	right ventricular failure ⁵⁸ ³⁰	Very rare (1%)	Very rare (<4-1%)	HP:0001708
23	reduced consciousness/confusion ⁵⁸		Frequent (79-30%)
24	congestive heart failure ⁵⁸		Frequent (79-30%)
25	left ventricular dysfunction ⁵⁸		Very frequent (99-80%)
26	elevated serum creatinine ⁵⁸		Occasional (29-5%)
27	abnormal ekg ⁵⁸		Very frequent (99-80%)

UMLS symptoms related to Cardiogenic Shock:

syncope; shock without mention of trauma

MGI Mouse Phenotypes related to Cardiogenic Shock:

⁴⁵

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	cardiovascular system	MP:0005385	9.02	NAA10 NPPA NPPB PIK3C2A PLAT

Sources

Drugs & Therapeutics for Cardiogenic Shock

PubMed Health treatment related to Cardiogenic Shock: ⁶³

Cardiogenic shock is life threatening and requires emergency medical treatment . The condition usually is diagnosed after a person has been admitted to a hospital for a heart attack . If the person isn't already in a hospital, emergency treatment can start as soon as medical personnel arrive. The first goal of emergency treatment for cardiogenic shock is to improve the flow of blood and oxygen to the body’s organs . Sometimes both the shock and its cause are treated at the same time. For example, doctors may quickly open a blocked blood vessel that's damaging the heart . Often, this can get the patient out of shock with little or no additional treatment .

Drugs for Cardiogenic Shock (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 76)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Benzocaine

Approved, Investigational

Phase 4

1994-09-7, 94-09-7

2337

Tannic acid

Approved

Phase 4

1401-55-4

16129878 16129778

Carbamide peroxide

Approved

Phase 4

124-43-6

Esmolol

Approved, Withdrawn

Phase 4

103598-03-4, 81147-92-4

59768

Abciximab

Approved

Phase 4

143653-53-6

3815015

Racepinephrine

Approved, Vet_approved

Phase 4

51-43-4, 329-65-7

838 5816

Dopamine

Approved

Phase 4

62-31-7, 51-61-6

681

Dobutamine

Approved

Phase 4

34368-04-2

36811

Milrinone

Approved

Phase 4

78415-72-2

4197

Cangrelor

Approved

Phase 4

163706-06-7

9854012

Ticagrelor

Approved

Phase 4

274693-27-5

9871419

Norepinephrine

Approved

Phase 4

51-41-2

439260

Simendan

Investigational

Phase 4

131741-08-7

Adrenergic beta-Antagonists

Phase 4

Adrenergic beta-1 Receptor Antagonists

Phase 4

Adrenergic Antagonists

Phase 4

Bronchodilator Agents

Phase 4

Anti-Asthmatic Agents

Phase 4

Respiratory System Agents

Phase 4

Mydriatics

Phase 4

Epinephryl borate

Phase 4

Cardiotonic Agents

Phase 4

Adrenergic beta-Agonists

Phase 4

Pharmaceutical Solutions

Phase 4

Protective Agents

Phase 4

Phosphodiesterase Inhibitors

Phase 4

Phosphodiesterase 3 Inhibitors

Phase 4

Purinergic P2Y Receptor Antagonists

Phase 4

Tin Fluorides

Phase 4

Vasoconstrictor Agents

Phase 4

Neurotransmitter Agents

Phase 4

Adrenergic Agonists

Phase 4

Adrenergic Agents

Phase 4

Sympathomimetics

Phase 4

Adrenergic alpha-Agonists

Phase 4

Platelet Aggregation Inhibitors

Phase 4

Fludrocortisone

Approved, Investigational

Phase 3

127-31-1

31378

Hydrocortisone succinate

Approved

Phase 3

2203-97-6

3643

Hydrocortisone acetate

Approved, Vet_approved

Phase 3

50-03-3

Hydrocortisone

Approved, Vet_approved

Phase 3

50-23-7

3640 5754

Nitric Oxide

Approved

Phase 3

10102-43-9

145068

Iodine

Approved, Investigational

Phase 3

7553-56-2

807

Anti-Inflammatory Agents

Phase 3

Hydrocortisone 17-butyrate 21-propionate

Phase 3

omega-N-Methylarginine

Phase 3

Heparin, bovine

Approved, Investigational, Withdrawn

Phase 2

9005-49-6

22833565 9812414 772

Pyruvate

Phase 2

Anticoagulants

Phase 2

Fibrinolytic Agents

Phase 2

Calcium, Dietary

Phase 2

Interventional clinical trials:

(show top 50) (show all 163)

#	Name	Status	NCT ID	Phase	Drugs
1	Effect of Ivabradine on Heart Rate and Hemodynamics in Patients With Stage D Heart Failure (HF)/Cardiogenic Shock on Dobutamine Treatment	Unknown status	NCT03387605	Phase 4	Ivabradine;Placebo
2	Efficacy and Safety on Heart Rate Control With Ivabradine on Cardiogenic Shock (ES-FISH)	Unknown status	NCT03437369	Phase 4	Ivabradine Oral Tablet
3	Impact of Early CRRT Intervention in Patients Receiving VA-ECMO Support on 30-day Mortality: A Randomized Controlled Trial	Unknown status	NCT03549923	Phase 4	Esmolol;Standard care
4	Left Ventricular Assist Device (Impella LP 2.5) vs. Intraaortic Balloon Counterpulsation (IABP) in Patients With Cardiogenic Shock and Acute Coronary Syndromes	Completed	NCT00417378	Phase 4
5	Randomized Clinical Study of Intraaortic Balloon Pump Use in Cardiogenic Shock Complicating Acute Myocardial Infarction	Completed	NCT00491036	Phase 4
6	Routine Upfront Abciximab Versus Standard Peri-Procedural Therapy in Patients Undergoing Percutaneous Coronary Intervention for Cardiogenic Shock PRAGUE-7 Trial.	Completed	NCT00420030	Phase 4	Abciximab
7	Prospective Randomized Multicenter Study Comparing Immediate Multivessel Revascularization by PCI Versus Culprit Lesion PCI With Staged Non-culprit Lesion Revascularization in Patients With Acute Myocardial Infarction Complicated by Cardiogenic Shock	Completed	NCT01927549	Phase 4
8	Randomized Clinical Study of Extra-Corporal Life Support in Cardiogenic Shock Complicating Acute Myocardial Infarction	Completed	NCT02544594	Phase 4
9	Optimizing the Use of Vasopressor After Coronary Reperfusion in Cardiogenic Shock Secondary to Myocardial Infarction. Pathophysiological Study Comparing the Efficacy and Cardio-circulatory Tolerability of Epinephrine and Norepinephrine	Completed	NCT01367743	Phase 4	epinephrine perfusion;norepinephrine perfusion
10	Comparison of Milrinone Versus Dobutamine in a Heterogeneous Population of Critically Ill Patients	Completed	NCT03207165	Phase 4	Milrinone;Dobutamine
11	Safety and Efficacy of Levosimendan in Patients With Acute Myocardial Infarction Complicated by Symptomatic Left Ventricular Failure.	Completed	NCT00324766	Phase 4	levosimendan;placebo,
12	Early Intra-aortic Balloon Pump Placement in Acute Decompensated Heart Failure Complicated by Cardiogenic Shock: a Randomized Clinical Trial	Recruiting	NCT04369573	Phase 4
13	Cangrelor Versus Ticagrelor In Patients With Acute Myocardial Infarction Complicated With Initial Cardiogenic Shock	Recruiting	NCT03551964	Phase 4	Cangrelor;Ticagrelor
14	CAPITAL DOREMI 2: Inotrope Versus Placebo Therapy for Cardiogenic Shock	Recruiting	NCT05267886	Phase 4	Dobutamine;Milrinone;Normal Saline
15	REvaSCUlarization StratEgy of Multivessel Coronary Artery Disease for Patients With Acute Myocardial Infarction Complicated by Cardiogenic SHOCK Undergoing Veno-arterial Extracorporeal Membrane Oxygenator: Randomized-Controlled Trial (RESCUE-SHOCK)	Not yet recruiting	NCT05527717	Phase 4
16	Clinical Outcome and Cost-effectiveness of Reduced Noradrenaline by Using a Lower Blood Pressure Target in Patients With Cardiogenic Shock From Acute Myocardial Infarction	Not yet recruiting	NCT05168462	Phase 4	Reduced noradrenaline use
17	National Multicenter Randomized Trial, Comparing Two Treatments of Myocardial Infarction Complicated With Cardiogenic Shock: Standard Treatment vs Standard Treatment Plus ECLS (Extracorporeal Life Support)	Terminated	NCT00314847	Phase 4
18	Prospective Comparison of ARNI to Alternate Oral Vasodilator Therapies to Determine the Hemodynamic Profile and Relative Tolerability of (ARNIs) in Patients With Decompensated Heart Failure and Low Cardiac Output	Withdrawn	NCT04206865	Phase 4	Sacubitril-Valsartan;Standard Oral Vasodilators
19	Norepinephrine vs Norepinephrine and Dobutamine in Cardiogenic Shock : a Randomised, Opened, Cross-over Study. Heart SHOCK-NORDOB Study	Unknown status	NCT03340779	Phase 3	Norepinephrine
20	Adjunctive Mild Hypothermia Therapy to Primary Percutaneous Coronary Intervention in Patients With Acute Myocardial Infarction Complicated With Shock: A Feasibility Study	Unknown status	NCT00846222	Phase 3
21	Efficacy of Levosimendan in the Critically Ill Patients With Unstable Hemodynamics (the LICI Study) - A Double Blind Randomized Pilot Study	Unknown status	NCT00093301	Phase 2, Phase 3	Levosimendan;Dobutamine
22	Shock Trial: Should We Emergently Revascularize Occluded Coronaries for Cardiogenic Shock.	Completed	NCT00000552	Phase 3	thrombolytic therapy
23	Investigator-initiated, Placebo-controlled, Double-blind, Multi-center, Randomized Trial to Assess the Efficacy and Safety of Adrecizumab in Subjects With Cardiogenic Shock	Completed	NCT03989531	Phase 2, Phase 3	Placebo
24	Effects of Adding Ivabradine in Patients With Cardiogenic Shock Requiring Inotropic Support	Recruiting	NCT05594342	Phase 3	Ivabradine 7.5Mg Tab;DOBUTamine Injectable Solution
25	Low Dose of Hydrocortisone and Fludrocortisone in Adult Cardiogenic Shock. A Multicenter, Prospective, Double-blind, Randomized, Placebo-controlled Study	Recruiting	NCT03773822	Phase 3
26	LEVOSIMENDAN to Facilitate Weaning From ECMO in Severe Cardiogenic Shock Patients	Recruiting	NCT04728932	Phase 3	Levosimendan;Placebo of Levosimendan
27	Effect of Early Use of Levosimendan Versus Placebo on Top of a Conventional Strategy of Inotrope Use on a Combined Morbidity-mortality Endpoint in Patients With Cardiogenic Shock	Not yet recruiting	NCT04020263	Phase 3	Levosimendan 2.5 MG/ML Injectable Solution;Placebo
28	Normoxemic Versus Hyperoxemic Extracorporeal Oxygenation : Impact on Organ Dysfunction in Patients Supported by Veino-arterial ECMO for Cardiogenic Shock	Not yet recruiting	NCT04990349	Phase 3	Oxygen gas
29	A Phase III International, Multi-Center, Prospective, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of Nitric Oxide Synthase Inhibition With Tilarginine Acetate Injection in Patients With Cardiogenic Shock Complicating Acute Myocardial Infarction, or the TRIUMPH Trial	Terminated	NCT00112281	Phase 3	Tilarginine Acetate Injection intravenous infusion
30	Phase II Clinical Trial for a Stepwise Progression in the Treatment of Cardiogenic Shock	Completed	NCT02591771	Phase 2	adrenaline
31	Effects of Pyruvate in Patients With Cardiogenic Shock and Intra-aortic Balloon Counterpulsation	Completed	NCT00604331	Phase 2	Pyruvate
32	A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study on the Safety and Efficacy of Istaroxime for Pre-Cardiogenic Shock	Recruiting	NCT04325035	Phase 2	Istaroxime;Placebo
33	Low-dose Dobutamine Infusion and Single-dose Tocilizumab in Acute Myocardial Infarction Patients With High Risk of Cardiogenic Shock Development - a 2x2 Multifactorial, Double-blinded, Randomized, Placebo Controlled Trial	Recruiting	NCT05350592	Phase 2	Tocilizumab;Dobutamine;NaCl 0.9%
34	Heparin Requirement in Counterpulsation	Terminated	NCT00445211	Phase 2	Heparin
35	Cyclosporine in Acute Myocardial Infarction Complicated by Cardiogenic Shock	Withdrawn	NCT01901471	Phase 2	Single bolus of Placebo of CicloMulsion® (Neurovive).;Single bolus of cyclosporine A (CicloMulsion®, Neurovive)
36	Use of Transtoracic Ecocargiogram With Calculation of Left Ventricular Volume Index in the Initial Adjustment of Initial Dose of Dobutamine in Patients With Heart Failure and Cardiogenic Shock	Unknown status	NCT03727282
37	SMart Angioplasty Research Team: A Multi-center, Open, REtrospective and Prospective Observational Study to Investigate Clinical oUtcomes and Efficacy of Left Ventricular Assist Device for Korean Patients With Cardiogenic Shock : RESCUE	Unknown status	NCT02985008
38	Levosimendan and Global Longitudinal Strain Assessment in Cardiogenic Shock Sepsis (GLASSES 1): a Study Protocol for an Observational Study	Unknown status	NCT04141410		Levosimendan
39	Hemodynamic Assessment in Cardiogenic Shock Regarding the Etiology	Unknown status	NCT03283995
40	Registry for Cardiogenic Shock: Utility and Efficacy of Device Therapy	Unknown status	NCT02790242
41	Prognostic Value of Circulating microRNAs in Patients With ST-elevation Myocardial Infarction (STEMI) Complicated by Cardiogenic Shock	Unknown status	NCT02691286
42	Use of Percutaneous Mitral Leaflet Approach for Severe Mitral Regurgitation in Cardiogenic Shock: Results From a Multicenter Observational Italian Experience (the Mitra-Shock Study).	Unknown status	NCT04399499
43	The Effects of Intra Aortic Balloon Pump Prior to Revascularization on Mortality of Patients With Acute Coronary Syndrome Complicated With Cardiogenic Shock	Unknown status	NCT03635840
44	Cardiogenic Shock Intravascular Cooling Trial (CHILL-SHOCK)	Unknown status	NCT03141255
45	Vasoplegia During VA-ECMO for Refractory Cardiogenic Shock : Descriptive Analysis of a Retrospective Cohort	Unknown status	NCT03968926
46	The Effect of Simultaneous Renal Replacement Therapy on Extracorporeal Membrane Oxygenation Support for Cardiogenic Shock Patients	Unknown status	NCT02870946
47	Levosimendan Efficacy for Veno-arterial ECMO Weaning: a Retrospective Study	Unknown status	NCT03346824
48	Post-Cardiotomy Extra-Corporeal Life Support Study: a Retrospective International Multicenter Cohort Study	Unknown status	NCT03857217
49	A Randomized, Controlled Trial: Hemoperfusion in Extracorporeal Membrane Oxygenation (ECMO) Patients	Unknown status	NCT03729765
50	Skeletal Muscle Oxygenation in Critically Ill	Unknown status	NCT00384644

Search NIH Clinical Center for Cardiogenic Shock

Inferred drug relations via UMLS ⁷¹ / NDF-RT ⁵⁰ :

Digitalis preparation

DIGITALIS,POWDERED

Digitoxin

Digoxin

Glucagon

Inamrinone

inamrinone lactate

Sources

Genetic Tests for Cardiogenic Shock

Sources

Anatomical Context for Cardiogenic Shock

Organs/tissues related to Cardiogenic Shock:

MalaCards : Heart, Skeletal Muscle, Kidney, Liver, Lung, Spinal Cord, Atrioventricular Node

Sources

Publications for Cardiogenic Shock

Articles related to Cardiogenic Shock:

(show top 50) (show all 13971)

#	Title	Authors	PMID	Year
1	Cardiac troponin I levels in acute pulmonary embolism. ⁵³ ⁶²	Margato R...Moreira JI	20222345	2009
2	Impaired plasma B-type natriuretic peptide clearance in human septic shock. ⁵³ ⁶²	Pirracchio R...Payen D	18679125	2008
3	Excimer laser in myocardial infarction: a comparison between STEMI patients with established Q-wave versus patients with non-STEMI (non-Q). ⁵³ ⁶²	CARMEL Excimer Laser Interventional Study Group...Das T	17426922	2008
4	B-type natriuretic peptide and its molecular precursor in myocardial infarction complicated by cardiogenic shock. ⁵³ ⁶²	Hejmdal A...Goetze JP	17448415	2007
5	Time-to-reperfusion therapy influences outcome of patients with myocardial infarction subjected to facilitated PCI. ⁵³ ⁶²	Dudek D...Dubiel JS	19758922	2005
6	Natriuretic peptides and E-selectin as predictors of acute deterioration in patients with inotrope-dependent heart failure. ⁵³ ⁶²	Potapov EV...Hetzer R	15848333	2005
7	Plasma brain natriuretic peptide reflects left ventricular function during percutaneous cardiopulmonary support. ⁵³ ⁶²	Ohata T...Izutani H	14726055	2004
8	Quantitative measurement of the novel human plasma protein, IHRP, by sandwich ELISA. ⁵³ ⁶²	Choi-Miura NH	11256472	2001
9	Frequency and clinical outcome of cardiogenic shock during acute myocardial infarction among patients receiving reteplase or alteplase. Results from GUSTO-III. Global Use of Strategies to Open Occluded Coronary Arteries. ⁵³ ⁶²	Hasdai D...Califf RM	10099909	1999
10	Impact of time to treatment with tissue plasminogen activator on morbidity and mortality following acute myocardial infarction (The second National Registry of Myocardial Infarction). ⁵³ ⁶²	Goldberg RJ...Gore JM	9708650	1998
11	[Factors predictive of early mortality after acute myocardial infarction]. ⁵³ ⁶²	Kaji Y...Ishihara Y	8953932	1996
12	Impella Versus Extracorporeal Membranous Oxygenation (ECMO) for Cardiogenic Shock: A Systematic Review and Meta-analysis. ⁶²	Ahmad S...Goldsweig AM	36174742	2023
13	Echocardiographic Characteristics of Cardiogenic Shock Patients with and Without Cardiac Arrest. ⁶²	Tabi M...Jentzer JC	35656768	2023
14	The critical care literature 2021. ⁶²	Winters ME...Brady WJ	36306647	2023
15	Risk of complications after a non-ST segment elevation acute myocardial infarction in a Latin-American cohort: An application of the ACTION ICU score. ⁶²	Vasquez-Rodriguez JF...Isaza D	36183629	2023
16	Correlation between severity of obesity and mortality in cardiogenic shock. ⁶²	Delfiner MS...Hamad E	36084397	2023
17	How does protocolization improve outcomes in cardiogenic shock due to end-stage heart failure? ⁶²	Lim HS	35931208	2022
18	Comment: Analysis of Bicarbonate-Based Purge Solution in Patients With Cardiogenic Shock Supported Via Impella Ventricular Device. ⁶²	Moretz JD...Bilazarian S	36458676	2022
19	Trends in Veno-Arterial Extracorporeal Life Support With and Without an Impella or Intra-Aortic Balloon Pump for Cardiogenic Shock. ⁶²	Hendrickson MJ...Qamar A	36420809	2022
20	Imaging for Transcatheter Mitral Valve Edge-to-Edge Repair for an Unusual Cause of Cardiogenic Shock. ⁶²	Lu ZN...Song G	36458532	2022
21	Phenotyping and Hemodynamic Assessment in Cardiogenic Shock: From Physiology to Clinical Application. ⁶²	Lim HS	36335176	2022
22	Author's response: "Peripheral blood neutrophil-to-lymphocyte ratio is associated with mortality across the spectrum of cardiogenic shock severity". ⁶²	Jentzer JC...Lawler PR	35105481	2022
23	Letter to the Editor: "Peripheral blood neutrophil-to-lymphocyte ratio is associated with mortality across the spectrum of cardiogenic shock severity". ⁶²	Magoon R...Jose J	35101338	2022
24	Cardiogenic Shock: Searching for a Better Lifeboat. ⁶²	Baran DA...Brozzi N	36420811	2022
25	Parameters associated with successful weaning of veno-arterial extracorporeal membrane oxygenation: a systematic review. ⁶²	Charbonneau F...Cavayas YA	36471408	2022
26	Impella Versus Intra-Aortic Balloon Pump for High-Risk PCI: A Propensity-Adjusted Large-Scale Claims Dataset Analysis. ⁶²	Lansky AJ...Parise H	36210212	2022
27	Corrigendum to "Venoarterial extracorporeal membrane oxygenation flow or dobutamine to improve microcirculation during ECMO for refractory cardiogenic shock" [Journal of Critical Care 71 (2022) Start page 1 - End page 1 /154090]. ⁶²	Chommeloux J...Schmidt M	36436880	2022
28	Inotropes, vasopressors, and mechanical circulatory support for treatment of cardiogenic shock complicating myocardial infarction: a systematic review and network meta-analysis. ⁶²	Fernando SM...Rochwerg B	36195825	2022
29	Cardiogenic shock due to yew poisoning rescued by VA-ECMO: case report and literature review. ⁶²	Schreiber N...Eller P	35942511	2022
30	Pharmacological treatment of cardiogenic shock - A state of the art review. ⁶²	Bruno RR...Jung C	35697151	2022
31	Use of extracorporeal membrane oxygenation in massive amlodipine overdose. ⁶²	Hong IZ...Ponampalam R	35986754	2022
32	Distinctive kidney function trajectories following left ventricular assist device implantation. ⁶²	Walther CP...Navaneethan SD	36182652	2022
33	Heart Failure After Right Ventricular Myocardial Infarction. ⁶²	Nagele MP...Flammer AJ	36197627	2022
34	Outcomes of isolated CABG from "OPCAB favor institution" for patients with left ventricular dysfunction. ⁶²	Itoda Y...Kanemura T	36462143	2022
35	Outcomes of Urgent Interhospital Transportation for Extracorporeal Membrane Oxygenation Patients. ⁶²	Yang JT...Ra YJ	36348506	2022
36	Implementation of an Electronic Health Records-Based Safe Contrast Limit for Preventing Contrast-Associated Acute Kidney Injury After Percutaneous Coronary Intervention. ⁶²	Yuan N...Ebinger JE	36475471	2022
37	Impact of ventricular arrhythmia on LVAD implantation admission outcomes. ⁶²	Ruge M...Rajapreyar I	35943857	2022
38	Mechanical Complications of Myocardial Infarction. ⁶²	Murphy A...Goldberg S	36075485	2022
39	Oxygen Therapy Confers Little Benefit in Patients with Acute ST-Segment Elevation Myocardial Infarction: A Systematic Review and Meta-Analysis. ⁶²	Wang X...He L	36455144	2022
40	Clinician and Algorithmic Application of the 2019 and 2022 Society of Cardiovascular Angiography and Intervention Shock Stages in the Critical Care Cardiology Trials Network Registry. ⁶²	Patel SM...CCCTN Investigators	36458542	2022
41	Surgically Implanted Impella Device for Patients on Impella CP Support Experiencing Refractory Hemolysis. ⁶²	Salas de Armas I...Gregoric ID	35348311	2022
42	Decreased Heart Rate Variability in COVID-19. ⁶²	Yin C...Xu L	36471860	2022
43	A Successful Case of Cardiac Arrest due to Acute Myocarditis with COVID-19: 120 Minutes on Manual Cardiopulmonary Resuscitation then Veno-Arterial Extracorporeal Membrane Oxygenation. ⁶²	Hoang BH...Nakahara S	36193699	2022
44	Clinical characteristics of patients with cardiac arrest induced by pesticide poisoning: Analysis of 15 cases. ⁶²	Jiang M...He F	36089421	2022
45	Contemporary Management of Concomitant Cardiac Arrest and Cardiogenic Shock Complicating Myocardial Infarction. ⁶²	Vallabhajosyula S...Jentzer JC	36464466	2022
46	Predictors and Hospital Outcomes in Pregnant Patients Undergoing Extracorporeal Membrane Oxygenation: A Nationwide Study. ⁶²	van den Bosch OFC...Balki M	36384013	2022
47	Safety and usefulness of left ventricular endomyocardial biopsy in new- onset acute heart failure requiring mechanical support by an Impella® device. ⁶²	Tschope C...Alogna A	35944774	2022
48	In-hospital mortality of COVID-19 patients hospitalized with ST-segment elevation myocardial infarction: A meta-analysis. ⁶²	Cheema HA...Lee KY	36411872	2022
49	Cardiovascular outcomes of transradial versus transfemoral percutaneous coronary intervention in End-Stage renal Disease: A Regression-Based comparison. ⁶²	Sattar Y...Chadi Alraies M	36051245	2022
50	Comparison of Pre- and Postnatally Diagnosed Coronary Artery Fistulae: Echocardiographic Features and Clinical Outcomes. ⁶²	Pisesky A...Hornberger LK	35940444	2022

Sources

Genes for Cardiogenic Shock

Genes related to Cardiogenic Shock (0 elite genes):

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubMed IDs
1	NPPB	Natriuretic Peptide B	Protein Coding	13.53	Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	15848333 14726055 20222345 (more) 18679125 17448415
2	PLAT	Plasminogen Activator, Tissue Type	Protein Coding	12.56	Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	10099909 19758922 9708650
3	NAA10	N-Alpha-Acetyltransferase 10, NatA Catalytic Subunit	Protein Coding	7.83	GeneCards inferred via : Disorders (show sections)
4	NPPA	Natriuretic Peptide A	Protein Coding	7.27	GeneCards inferred via : Publications (show sections)
5	PIK3C2A	Phosphatidylinositol-4-Phosphate 3-Kinase Catalytic Subunit Type 2 Alpha	Protein Coding	6.84	Novoseek inferred ⁵³	8953932 17426922
6	ITIH4	Inter-Alpha-Trypsin Inhibitor Heavy Chain 4	Protein Coding	2.04	Novoseek inferred ⁵³	11256472

Sources

Variations for Cardiogenic Shock

Sources

Expression for Cardiogenic Shock

Search GEO for disease gene expression data for Cardiogenic Shock.

Sources

Pathways for Cardiogenic Shock

Pathways related to Cardiogenic Shock according to GeneCards Suite gene sharing:

#	Super pathways	Score	Top Affiliating Genes
1	MicroRNAs in cardiomyocyte hypertrophy ⁷⁴ Show member pathways Cardiac hypertrophic response ⁷⁴	11.32	NPPB NPPA
2	NO/cGMP/PKG mediated neuroprotection ⁷⁴	10.6	NPPB NPPA
3	Cardiomyocyte Differentiation through BMP Receptors ⁶⁴	9.97	NPPB NPPA

Sources

GO Terms for Cardiogenic Shock

Cellular components related to Cardiogenic Shock according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	collagen-containing extracellular matrix	GO:0062023	9.02	PLAT NPPA ITIH4

Biological processes related to Cardiogenic Shock according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	vasodilation	GO:0042311	9.73	NPPB NPPA
2	platelet-derived growth factor receptor signaling pathway	GO:0048008	9.71	PLAT PIK3C2A
3	cGMP-mediated signaling	GO:0019934	9.62	NPPB NPPA
4	cardiac conduction system development	GO:0003161	9.56	NPPB NPPA
5	blood vessel diameter maintenance	GO:0097746	9.54	NPPB NPPA
6	negative regulation of systemic arterial blood pressure	GO:0003085	9.46	NPPB NPPA
7	cGMP biosynthetic process	GO:0006182	9.26	NPPB NPPA
8	receptor guanylyl cyclase signaling pathway	GO:0007168	8.92	NPPB NPPA